Liquidia Corporation Email Format
Biotechnology ResearchNorth Carolina, United States201-500 Employees
Liquidia Corporation operates in biotechnology research, focusing on developing and commercializing inhalation therapies for pulmonary hypertension and related vascular conditions through its PRINT technology. Its lead product, YUTREPIA, is a treprostinil inhalation powder intended for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company is also advancing L606, a liposomal treprostinil formulation designed for twice-daily administration with a short-duration next-generation nebulizer in North America. Its Liquidia PAH subsidiary handles the commercialization of generic Treprostinil Injection for pulmonary disease. Based in Morrisville, North Carolina, the firm serves patients with challenging cardiopulmonary conditions and participates in scientific conferences to share research, including a 2026 event in Dallas where it announced plans to present four posters at the PHA conference.